A report on Japan's infusion therapy market has been released, forecasting that the market will grow from approximately US$363 million in 2025 to approximately US$6.75 billion by 2035. The adoption of home infusion therapy and portable pumps is expected to increase going forward.
株式会社マーケットリサーチセンター has released "Japan Infusion Therapy Market (2026-2035)," a report covering Japan's market size and trends, segment-by-segment forecasts, and information on related companies. The report outlines the overall infusion therapy market and its key drivers, and presents the outlook for the Japanese market.
The market was valued at approximately US$3.63 billion as of 2025 and is projected to expand at a CAGR of 6.4% from 2026 to 2035, reaching approximately US$6.75 billion by 2035. Growth drivers include the rising number of patients with chronic diseases and cancer, population aging, growing demand for home healthcare, advances in infusion devices, and progress in regulatory approvals.
The expansion of home healthcare is identified as a key growth driver, with demand for infusion therapy expected to increase not only in hospitals but also in outpatient and home healthcare settings. In 2024, KORU Medical Systems' FreedomEdge Infusion System reportedly received regulatory approval in Japan and is cited as an example symbolizing the expansion of the home infusion therapy market.
By treatment type, antibiotics and antivirals have long accounted for the largest share, but demand in oncology and the importance of advanced infusion pumps are expected to increase. Patient-centered drug delivery and remote monitoring, including portable pumps, smart delivery systems, and home-based immunoglobulin therapy, are identified as key sources of competitiveness.